Evolution of liver transplantation in the metabolic dysfunction-associated steatotic liver disease era: Tracking impact through time

Table 2 Recurrence or de novo steatosis post liver transplant

Ref.	Population	Recurrence/de novo steatosis
Tokodai et al[47]	95 patients: NASH 27, ALD 68	Recurrence 41% in NASH patients
O’Neill et al[24]	279 patients: NAFLD 84, ALD 195	Recurrence 20% in NAFLD patients
Van Herck et al[5]	232 patients: NAFLD 112, HCV 120	Recurrence 429% in NAFLD patients (mean at 3 years): -12.8% at 1 year, -23.7% at 3 years, -43.5% at 5 years
Sourianarayanane et al[25]	185 patients: NASH 77, ALD 108	Recurrence 546% at 1 year in NASH patients
Bhagat et al[30]	154 patients: NASH 71, ALD 83	Recurrence in 33% after 6 months in NASH patients
Castelló et al[35]	54 patients: NASH 18, ALD 36	Recurrence in 20% in NASH patients at 1 year and 30% at 3 years
Unger et al[33]	27 patients: NASH 15, Cryptogenic 12	Recurrence in 20% after 6 months in NASH patients

NASH: Non-alcoholic steatohepatitis; ALD: Alcohol-associated liver disease; HCV: Hepatitis C virus; NAFLD: Non-alcoholic fatty liver disease; LT: Liver transplant.